| 证券代码 | EGLT.O |
| 证券名称 | Egalet Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-02-06 |
| 首发价格(元) | 12 USD |
| 首发数量(股) | 4200000 |
| 首发募资额(元) | 50,400,000.00 USD |
| 首发主承销商 | JMP Securities LLC,Stifel Nicolaus & Company, Incorporated |
| 货币单位 | USD |
| 公司名称 | Egalet Corporation |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 600 Lee Road, Suite 100, Wayne, Pennsylvania, USA |
| 成立日期 | 2013-08 |
| 董事会主席 | Timothy P. Walbert |
| 公司属地 | United States 美国 |
| 公司网址 | www.egalet.com |
| 电话 | +1 (610) 833-4200 |
| 传真 | - |
| 公司简介 | Egalet Corporation is a fully integrated specialty pharmaceutical company developing, manufacturing and commercializing innovative treatments for pain and other conditions. Given the need for acute and chronic pain products and the issue of prescription opioid abuse, Egalet is focused on bringing non-narcotic products and abuse-deterrent formulations of opioids to patients and healthcare providers. Egalet also has a pipeline of products developed using Guardian Technology which it may look to partner. The Company plans to continue to grow revenues of its three commercial products, explore business development opportunities and leverage its proprietary Guardian Technology. |